A citation-based method for searching scientific literature

Paolo Tarantino, Luca Mazzarella, Antonio Marra, Dario Trapani, Giuseppe Curigliano. Cancer Treat Rev 2021
Times Cited: 4







List of co-cited articles
12 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).
F Cardoso, S Paluch-Shimon, E Senkus, G Curigliano, M S Aapro, F André, C H Barrios, J Bergh, G S Bhattacharyya, L Biganzoli,[...]. Ann Oncol 2020
286
75

Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.
Aurélien Marabelle, Marwan Fakih, Juanita Lopez, Manisha Shah, Ronnie Shapira-Frommer, Kazuhiko Nakagawa, Hyun Cheol Chung, Hedy L Kindler, Jose A Lopez-Martin, Wilson H Miller,[...]. Lancet Oncol 2020
540
75

Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children.
Alexander Drilon, Theodore W Laetsch, Shivaani Kummar, Steven G DuBois, Ulrik N Lassen, George D Demetri, Michael Nathenson, Robert C Doebele, Anna F Farago, Alberto S Pappo,[...]. N Engl J Med 2018
50

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
Robert C Doebele, Alexander Drilon, Luis Paz-Ares, Salvatore Siena, Alice T Shaw, Anna F Farago, Collin M Blakely, Takashi Seto, Byung Chul Cho, Diego Tosi,[...]. Lancet Oncol 2020
449
50

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study.
Aurelien Marabelle, Dung T Le, Paolo A Ascierto, Anna Maria Di Giacomo, Ana De Jesus-Acosta, Jean-Pierre Delord, Ravit Geva, Maya Gottfried, Nicolas Penel, Aaron R Hansen,[...]. J Clin Oncol 2020
768
50

FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.
Leigh Marcus, Steven J Lemery, Patricia Keegan, Richard Pazdur. Clin Cancer Res 2019
424
50

Prevalence and mutational determinants of high tumor mutation burden in breast cancer.
R Barroso-Sousa, E Jain, O Cohen, D Kim, J Buendia-Buendia, E Winer, N Lin, S M Tolaney, N Wagle. Ann Oncol 2020
97
50

Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.
David S Hong, Steven G DuBois, Shivaani Kummar, Anna F Farago, Catherine M Albert, Kristoffer S Rohrberg, Cornelis M van Tilburg, Ramamoorthy Nagasubramanian, Jordan D Berlin, Noah Federman,[...]. Lancet Oncol 2020
285
50

Tumor Mutational Burden and PTEN Alterations as Molecular Correlates of Response to PD-1/L1 Blockade in Metastatic Triple-Negative Breast Cancer.
Romualdo Barroso-Sousa, Tanya E Keenan, Sonia Pernas, Pedro Exman, Esha Jain, Ana C Garrido-Castro, Melissa Hughes, Brittany Bychkovsky, Renato Umeton, Janet L Files,[...]. Clin Cancer Res 2020
71
50

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, Hao Wang, Bjarne R Bartlett, Holly Kemberling, Aleksandra D Eyring, Andrew D Skora, Brandon S Luber, Nilofer S Azad, Dan Laheru,[...]. N Engl J Med 2015
50

Histology-agnostic drug development - considering issues beyond the tissue.
Roberto Carmagnani Pestana, Shiraj Sen, Brian P Hobbs, David S Hong. Nat Rev Clin Oncol 2020
27
50

Sacituzumab govitecan in previously treated hormone receptor-positive/HER2-negative metastatic breast cancer: final results from a phase I/II, single-arm, basket trial.
K Kalinsky, J R Diamond, L T Vahdat, S M Tolaney, D Juric, J O'Shaughnessy, R L Moroose, I A Mayer, V G Abramson, D M Goldenberg,[...]. Ann Oncol 2020
36
50

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers.
Aaron M Goodman, Shumei Kato, Lyudmila Bazhenova, Sandip P Patel, Garrett M Frampton, Vincent Miller, Philip J Stephens, Gregory A Daniels, Razelle Kurzrock. Mol Cancer Ther 2017
25

First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer.
Alice T Shaw, Todd M Bauer, Filippo de Marinis, Enriqueta Felip, Yasushi Goto, Geoffrey Liu, Julien Mazieres, Dong-Wan Kim, Tony Mok, Anna Polli,[...]. N Engl J Med 2020
209
25

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.
Hyuna Sung, Jacques Ferlay, Rebecca L Siegel, Mathieu Laversanne, Isabelle Soerjomataram, Ahmedin Jemal, Freddie Bray. CA Cancer J Clin 2021
25

Landscape of Microsatellite Instability Across 39 Cancer Types.
Russell Bonneville, Melanie A Krook, Esko A Kautto, Jharna Miya, Michele R Wing, Hui-Zi Chen, Julie W Reeser, Lianbo Yu, Sameek Roychowdhury. JCO Precis Oncol 2017
412
25

Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
R Condorelli, F Mosele, B Verret, T Bachelot, P L Bedard, J Cortes, D M Hyman, D Juric, I Krop, I Bieche,[...]. Ann Oncol 2019
51
25

Durable Complete Response With Immune Checkpoint Inhibitor in Breast Cancer With High Tumor Mutational Burden and APOBEC Signature.
Saranya Chumsri, Ethan S Sokol, Aixa E Soyano-Muller, Ricardo D Parrondo, Gina A Reynolds, Aziza Nassar, E Aubrey Thompson. J Natl Compr Canc Netw 2020
10
25

Detection of Mismatch Repair Deficiency and Microsatellite Instability in Colorectal Adenocarcinoma by Targeted Next-Generation Sequencing.
Jonathan A Nowak, Matthew B Yurgelun, Jacqueline L Bruce, Vanesa Rojas-Rudilla, Dimity L Hall, Priyanka Shivdasani, Elizabeth P Garcia, Agoston T Agoston, Amitabh Srivastava, Shuji Ogino,[...]. J Mol Diagn 2017
98
25

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project.
Diana M Merino, Lisa M McShane, David Fabrizio, Vincent Funari, Shu-Jen Chen, James R White, Paul Wenz, Jonathan Baden, J Carl Barrett, Ruchi Chaudhary,[...]. J Immunother Cancer 2020
134
25

Absence of microsatellite instability in mucinous carcinomas of the breast.
Magali Lacroix-Triki, Maryou B Lambros, Felipe C Geyer, Paula H Suarez, Jorge S Reis-Filho, Britta Weigelt. Int J Clin Exp Pathol 2010
13
25

Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrum.
Marick Laé, Paul Fréneaux, Xavier Sastre-Garau, Olfa Chouchane, Brigitte Sigal-Zafrani, Anne Vincent-Salomon. Mod Pathol 2009
111
25

Microsatellite instability and immune checkpoint inhibitors: toward precision medicine against gastrointestinal and hepatobiliary cancers.
Yuji Eso, Takahiro Shimizu, Haruhiko Takeda, Atsushi Takai, Hiroyuki Marusawa. J Gastroenterol 2020
52
25


Genomic characterization of metastatic breast cancers.
François Bertucci, Charlotte K Y Ng, Anne Patsouris, Nathalie Droin, Salvatore Piscuoglio, Nadine Carbuccia, Jean Charles Soria, Alicia Tran Dien, Yahia Adnani, Maud Kamal,[...]. Nature 2019
271
25

An optimized pentaplex PCR for detecting DNA mismatch repair-deficient colorectal cancers.
Ajay Goel, Takeshi Nagasaka, Richard Hamelin, C Richard Boland. PLoS One 2010
106
25

Phase III study of selpercatinib versus chemotherapy ± pembrolizumab in untreated RET positive non-small-cell lung cancer.
Benjamin J Solomon, Cai Cun Zhou, Alexander Drilon, Keunchil Park, Jürgen Wolf, Yasir Elamin, Hannah M Davis, Victoria Soldatenkova, Andreas Sashegyi, Aimee Bence Lin,[...]. Future Oncol 2021
12
25

Secretory carcinoma of the breast: results from the survival, epidemiology and end results database.
David P Horowitz, Charu S Sharma, Eileen Connolly, Daniela Gidea-Addeo, Israel Deutsch. Breast 2012
59
25

JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
T Yoshino, G Pentheroudakis, S Mishima, M J Overman, K-H Yeh, E Baba, Y Naito, F Calvo, A Saxena, L-T Chen,[...]. Ann Oncol 2020
38
25

Molecular characterization of cancers with NTRK gene fusions.
Zoran Gatalica, Joanne Xiu, Jeffrey Swensen, Semir Vranic. Mod Pathol 2019
233
25


Genomic profiling of breast secretory carcinomas reveals distinct genetics from other breast cancers and similarity to mammary analog secretory carcinomas.
Gregor Krings, Nancy M Joseph, Gregory R Bean, David Solomon, Courtney Onodera, Eric Talevich, Iwei Yeh, James P Grenert, Elizabeth Hosfield, Emily D Crawford,[...]. Mod Pathol 2017
39
25

Microsatellite instability: a review of what the oncologist should know.
Kai Li, Haiqing Luo, Lianfang Huang, Hui Luo, Xiao Zhu. Cancer Cell Int 2020
107
25

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.
James P Solomon, Irina Linkov, Andrea Rosado, Kerry Mullaney, Ezra Y Rosen, Denise Frosina, Achim A Jungbluth, Ahmet Zehir, Ryma Benayed, Alexander Drilon,[...]. Mod Pathol 2020
197
25

Advances in Targeting RET-Dependent Cancers.
Vivek Subbiah, Gilbert J Cote. Cancer Discov 2020
44
25

ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research.
C Marchiò, M Scaltriti, M Ladanyi, A J Iafrate, F Bibeau, M Dietel, J F Hechtman, T Troiani, F López-Rios, J-Y Douillard,[...]. Ann Oncol 2019
147
25

Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential.
Raza S Hoda, Edi Brogi, Fresia Pareja, Gouri Nanjangud, Melissa P Murray, Britta Weigelt, Jorge S Reis-Filho, Hannah Y Wen. Histopathology 2019
22
25

Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base.
John Doromal Jacob, Caitlin Hodge, Jan Franko, Christopher M Pezzi, Charles D Goldman, Vicki Suzanne Klimberg. J Surg Oncol 2016
23
25

Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer.
Song Ee Park, Kyunghee Park, Eunjin Lee, Ji-Yeon Kim, Jin Seok Ahn, Young-Hyuck Im, Choonghoon Lee, Hun Jung, Soo Youn Cho, Woong-Yang Park,[...]. Oncoimmunology 2018
33
25

DNA mismatch repair deficiency in breast carcinoma: a pilot study of triple-negative and non-triple-negative tumors.
Yong H Wen, Edi Brogi, Zhaoshi Zeng, Muzaffar Akram, Jeff Catalano, Philip B Paty, Larry Norton, Jinru Shia. Am J Surg Pathol 2012
31
25

Targeted Next Generation Sequencing Identifies Markers of Response to PD-1 Blockade.
Douglas B Johnson, Garrett M Frampton, Matthew J Rioth, Erik Yusko, Yaomin Xu, Xingyi Guo, Riley C Ennis, David Fabrizio, Zachary R Chalmers, Joel Greenbowe,[...]. Cancer Immunol Res 2016
314
25

Global analysis of advanced/metastatic breast cancer: Decade report (2005-2015).
Fatima Cardoso, Danielle Spence, Shirley Mertz, Dian Corneliussen-James, Kimberly Sabelko, Julie Gralow, Maria-João Cardoso, Fedro Peccatori, Diego Paonessa, Ann Benares,[...]. Breast 2018
97
25

Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden.
Matthew D Hellmann, Tudor-Eliade Ciuleanu, Adam Pluzanski, Jong Seok Lee, Gregory A Otterson, Clarisse Audigier-Valette, Elisa Minenza, Helena Linardou, Sjaak Burgers, Pamela Salman,[...]. N Engl J Med 2018
25

A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
J Mateo, D Chakravarty, R Dienstmann, S Jezdic, A Gonzalez-Perez, N Lopez-Bigas, C K Y Ng, P L Bedard, G Tortora, J-Y Douillard,[...]. Ann Oncol 2018
179
25

Pan-TRK Immunohistochemistry: A Useful Diagnostic Adjunct For Secretory Carcinoma of the Breast.
Beth T Harrison, Elizabeth Fowler, Gregor Krings, Yunn-Yi Chen, Gregory R Bean, Anne Vincent-Salomon, Laetitia Fuhrmann, Sandra E Barnick, Beiyun Chen, Elizabeth M Hosfield,[...]. Am J Surg Pathol 2019
27
25


Tumor mutational burden standardization initiatives: Recommendations for consistent tumor mutational burden assessment in clinical samples to guide immunotherapy treatment decisions.
Albrecht Stenzinger, Jeffrey D Allen, Jörg Maas, Mark D Stewart, Diana M Merino, Madison M Wempe, Manfred Dietel. Genes Chromosomes Cancer 2019
103
25

Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, Kellie N Smith, Hao Wang, Bjarne R Bartlett, Laveet K Aulakh, Steve Lu, Holly Kemberling, Cara Wilt, Brandon S Luber,[...]. Science 2017
25

Identifying patients with NTRK fusion cancer.
J P Solomon, R Benayed, J F Hechtman, M Ladanyi. Ann Oncol 2019
98
25

Pan-Trk Immunohistochemistry Identifies NTRK Rearrangements in Pediatric Mesenchymal Tumors.
Erin R Rudzinski, Christina M Lockwood, Bradley A Stohr, Sara O Vargas, Rachel Sheridan, Jennifer O Black, Veena Rajaram, Theodore W Laetsch, Jessica L Davis. Am J Surg Pathol 2018
112
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.